Gastrik Pepsinojen Ⅰ ve Ⅱ/Gastrin-17'nin Helicobacter pylori antikor test kitleriyle birlikte kullanılmasıyla mide kanseri taramasında klinik değer
Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Early detection and diagnosis are crucial for improving survival rates. In recent years, the combined use of gastric pepsinogen I (PGI), gastric pepsinogen II (PGII), gastrin-17 (G-17) assay kits together with that of Helicobacter pylori (H. pylori) antibodies has shown promise in the field of gastric cancer screening.
PGI, PGII, and G-17 are biomarkers that play important roles in the pathogenesis of gastric cancer. Decreased levels of PGI and increased levels of PGII are associated with an increased risk of gastric cancer. Additionally, elevated levels of G-17 have been found in patients with gastric cancer. Therefore, measuring the levels of these biomarkers can provide valuable information for the early detection of gastric cancer.
H. pylori infection is a well-known risk factor for gastric cancer. The presence of H. pylori antibodies in the blood indicates the presence of the bacteria and an increasing risk of developing gastric cancer. Therefore, combining the measurement of H. pylori antibodies with the aforementioned biomarkers can enhance the accuracy and reliability of gastric cancer screening.
The diagnostic Kit for Pepsinogen I/Pepsinogen Ⅱ/Gastrin-17 (fluorescence immunochromatographic assay) independently developed and produced by Xiamen Wiz Biotech Co., Ltd. have several clinical advantages. Firstly, it is a non-invasive method that can be easily performed in outpatient settings. This reduces patient discomfort and increases compliance with screening programs; Secondly, it has been shown to have high sensitivity and specificity in detecting gastric cancer, especially in the early stages. This allows for the timely initiation of treatment, leading to improved patient outcomes; Lastly, it is cost-effective compared to other screening methods such as endoscopy.
Xiamen Wiz Biotech Co., Ltd is a high-tech company engaging in researching and developing, producing and selling of rapid diagnostic reagents and the analyzing instruments. Focusing on technological innovation, WIZBIOTECH would like to take the advantage of existing channels to expand more medical markets, with a view to contribute more in the field of rapid diagnostic POCT.
